EICHORPublic-registry site landscape for NCT05397600, “Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients”, a Glaucoma study sponsored by Laboratoires Thea. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05397600 (registry record) |
| Study title | Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients |
| Sponsor | Laboratoires Thea |
| Condition(s) | Glaucoma; Ocular Hypertension |
| Phase | PHASE3 |
| Listed sites | 64 |
| Site countries | United States, Canada, Colombia |
Patient-friendly overview of this study: eichor.com/study/NCT05397600.
Eichor generates a preliminary site-risk snapshot for NCT05397600 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Glaucoma trials
← Eichor home · All tracked trials · Glaucoma studies · Weekly briefs
